
Lantern Pharma (LTRN) Stock
Lantern Pharma Chart
Company Profile
Price: $5.30
Market Cap: $57.16M
Exchange: NASDAQ
CEO: Mr. Panna Sharma PH.D.
Sector: Healthcare
Industry: Biotechnology
Employees: -0.00B
Headquarters: Dallas, TX
Website: Lantern Pharma
Business Summary
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Lantern Pharma News
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that the first patient has been enrolled and dosed in Taiwan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The enrollment of the first patie.

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Triple Negative Breast Cancer (TNBC). This marks the second Fast Track Designation received for LP-184 in 2024, following its designation for.

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence company transforming oncology drug development, and its wholly-owned subsidiary Starlight Therapeutics, focused exclusively on CNS and brain cancers, today announced the presentation of new preclinical data and Phase 1b trial design for LP-184 (to be developed as STAR-001 for CNS indications) in glioblastoma at the Society for Neuro-Oncology (SNO) 2024 Annual Meeting in Houston, Texas. The poster presentatio.

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Operator Good afternoon, and welcome to our Third Quarter 2024 earnings call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter 2024, ending September 30, 2024. "Lantern is achieving remarkable momentum, balancing meticulous execution with innovation. While progressing on.

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
DALLAS--(BUSINESS WIRE)--Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the formation of a Scientific Advisory Board (“SAB”) to support the development of lead compound STAR-001. The inaugural SAB will work closely with Starlight's management team to provide strategic guidance and critical expert insights into the development of STAR-001 in CNS and bra.

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2024 operating and financial results webcast on Thursday, November 7, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial.

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference on Wednesday, October 30, 2024, at 10:30 a.m. ET at the Mandarin Oriental in New York, NY. Webcast Link: https://www.meetmax.com/sched/event_106721/conference_register.html Confe.

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Glioblastoma. LP-184 is currently in a Phase 1A clinical trial designed to evaluate the safety and tolerability of the synthetically lethal in.

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that the company has been granted three rare pediatric disease designations (RPDD) by the FDA. Lantern was granted these rare pediatric disease designations in: malignant rhabdoid tumors (MRT), rhabdomyosarcoma (.

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Dr. Reggie Ewesuedo - Vice President, Clinical Development Conference Call Participants John Vandermosten - Zacks Research Operator Good afternoon. And welcome to our Second Quarter 2024 Earnings Call.

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc., (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced that the Japan Patent Office (JPO) has issued a Certificate of Patent for patent application no. 2021-513267 / registration no. 7489966 directed to Lantern Pharma's drug candidate LP-284 ((+)N-hydroxy-N-(methyla.

The 3 Best Machine Learning Stocks to Quadruple Your Money by 2035
One of the hottest investment trends to jump on at the moment is machine learning stocks to buy. Valued at about $79.3 billion at the moment, it's expected to balloon to $503.4 billion by the time 2030 rolls around, according to Statista.

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the first quarter 2024, ended March 31, 2024. “Our company made meaningful progress across multiple clinical trials and in furthering our AI platform this past qua.

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
PARIS & DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI)(1) inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern will be leveraging its proprietary RADR® AI platform to uncover bi.

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2024 financial results webcast on Thursday, May 9, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the.

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that – the company has launched Webinar Wednesdays, a webinar series that focuses on areas of high oncology drug development interest with leading physicians, scientists and Lantern collaborators in drug developm.

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population. Dr. Yashushi Goto a leading lung cancer clinician-scientist at the renowned National Cancer Center of Japan will be a lead investigator. DALLAS–(BUSINESS WIRE)–Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing … The post Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lu...

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2023. “This past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for o.

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced the dosing of the first two patients in the Phase 1 clinical trial evaluating Lantern's investigational new drug LP-284 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), including mantle cell ly.

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2023 financial results webcast on Monday, March 18, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial.

Lantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW. The conference will be on Thursday, March 7th, and is a virtual event. Lantern Pharma's CEO, Mr. Panna Sharma, will be discussing and presenting via a fireside chat format at The 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference at approximately 2 pm E.

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
DALLAS--(BUSINESS WIRE)--Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D. has joined Starlight as its Chief Medical Officer. Dr. Chamberlain will oversee Starlight's clinical operations, which currently include planned clinical trials for glioblastoma and other high-grade gliomas,.

Lantern Pharma Inc. (LTRN) Q3 2023 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Panna Sharma - President and Chief Executive Officer David Margrave - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to our Third Quarter 2023 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode.

Lantern Pharma Earnings
This section highlights Lantern Pharma's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
---|---|---|---|---|---|
Read Transcript | Q3 | 2024 | 2024-11-08 | N/A | N/A |
Read Transcript | Q1 | 2024 | 2024-05-09 | $-0.43 | $-0.51 |
Read Transcript | Q4 | 2023 | 2024-03-18 | $-0.40 | $-0.39 |
Read Transcript | Q3 | 2023 | 2023-11-09 | N/A | N/A |
Read Transcript | Q2 | 2023 | 2023-08-09 | $-0.40 | $-0.44 |
Read Transcript | Q1 | 2023 | 2023-05-13 | N/A | N/A |
Financial Statements
Access annual & quarterly financial statements for Lantern Pharma, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Revenue | $- | $- | $- | $- | $- |
Cost of Revenue | $174.84K | $154.68K | $97.42K | $3.39K | $1.63K |
Gross Profit | $-174.84K | $-154.68K | $-97.42K | $-3.39K | $-1.63K |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research and Development Expenses | $11.89M | $8.60M | $7.57M | $2.24M | $953.18K |
General and Administrative Expenses | $5.98M | $5.83M | $5.02M | $3.66M | $1.48M |
Selling and Marketing Expenses | $- | $- | $- | $- | $- |
Selling General and Administrative Expenses | $5.98M | $5.83M | $5.02M | $3.66M | $1.48M |
Other Expenses | $- | $-31.55K | $160.55K | $- | $- |
Operating Expenses | $17.88M | $14.43M | $12.59M | $5.91M | $2.43M |
Cost and Expenses | $17.88M | $14.43M | $12.59M | $5.91M | $2.43M |
Interest Income | $765.39K | $204.35K | $67.93K | $- | $- |
Interest Expense | $- | $204.35K | $- | $- | $- |
Depreciation and Amortization | $174.84K | $154.68K | $97.42K | $3.39K | $1.63K |
EBITDA | $-15.79M | $-14.42M | $-12.27M | $-5.90M | $-2.43M |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | $-17.88M | $-14.43M | $-12.59M | $-5.91M | $-2.43M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income Expenses Net | $1.92M | $172.81K | $228.48K | $- | $- |
Income Before Tax | $-15.96M | $-14.26M | $-12.36M | $-5.91M | $-2.43M |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | $- | $-172.81K | $-67.93K | $-202.91K | $--0.00B |
Net Income | $-15.96M | $-14.09M | $-12.30M | $-5.91M | $-2.43M |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | $-1.47 | $-1.30 | $-1.13 | $-0.95 | $-0.39 |
EPS Diluted | $-1.47 | $-1.30 | $-1.13 | $-0.95 | $-0.39 |
Weighted Average Shares Outstanding | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M |
Weighted Average Shares Outstanding Diluted | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M |
SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $- | $- | $- | $261.05K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Cost of Revenue | $- | $46.27K | $4.06K | $44.32K | $43.33K | $43.76K | $43.44K | $- | $39.10K | $38.53K | $38.14K | $71.10K | $- | $25.68K | $1.34K | $- | $- | $- | $- | $- |
Gross Profit | $- | $-46.27K | $-4.06K | $216.74K | $-43.33K | $-43.76K | $-43.44K | $- | $-39.10K | $-38.53K | $-38.14K | $-71.10K | $- | $-25.68K | $-1.34K | $- | $- | $- | $- | $- |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 83.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research and Development Expenses | $3.72M | $3.89M | $4.25M | $3.57M | $2.21M | $3.56M | $2.55M | $2.25M | $702.30K | $2.99M | $2.66M | $2.16M | $2.96M | $1.16M | $1.28M | $1.35M | $600.77K | $157.02K | $137.10K | $177.47K |
General and Administrative Expenses | $1.46M | $1.52M | $1.48M | $1.30M | $1.31M | $1.63M | $1.73M | $1.57M | $1.44M | $1.41M | $1.41M | $1.35M | $1.18M | $1.31M | $1.17M | $1.55M | $1.10M | $676.40K | $340.17K | $497.70K |
Selling and Marketing Expenses | $- | $-46.27K | $-4.06K | $-44.32K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Selling General and Administrative Expenses | $1.46M | $1.47M | $1.48M | $1.26M | $1.31M | $1.63M | $1.73M | $1.57M | $1.44M | $1.41M | $1.41M | $1.35M | $1.18M | $1.31M | $1.17M | $1.55M | $1.10M | $676.40K | $340.17K | $497.70K |
Other Expenses | $- | $260.30K | $90.24K | $424.07K | $115.78K | $326.08K | $284.72K | $- | $-171.65K | $-152.59K | $-77.80K | $28.15K | $17.68K | $114.72K | $- | $- | $- | $- | $- | $- |
Operating Expenses | $5.18M | $5.36M | $5.73M | $4.83M | $3.52M | $5.19M | $4.29M | $3.83M | $2.15M | $4.39M | $4.07M | $3.51M | $4.15M | $2.48M | $2.45M | $2.90M | $1.70M | $833.42K | $477.28K | $675.17K |
Cost and Expenses | $5.18M | $5.41M | $5.73M | $4.88M | $3.52M | $5.19M | $4.29M | $3.83M | $2.15M | $4.39M | $4.07M | $3.51M | $4.15M | $2.48M | $2.45M | $2.90M | $1.70M | $833.42K | $477.28K | $675.17K |
Interest Income | $191.35K | $188.66K | $200.95K | $267.39K | $246.39K | $117.82K | $133.78K | $74.68K | $52.22K | $55.03K | $22.42K | $- | $77.22K | $47.89K | $- | $- | $- | $- | $- | $- |
Interest Expense | $- | $- | $- | $418.50K | $- | $- | $- | $- | $52.22K | $55.03K | $22.42K | $29.03K | $- | $- | $- | $- | $- | $- | $- | $- |
Depreciation and Amortization | $4.39K | $46.27K | $4.06K | $44.32K | $43.33K | $43.76K | $43.44K | $2.76K | $39.10K | $38.53K | $38.14K | $71.10K | $1.85K | $25.68K | $1.34K | $1.09K | $1.09K | $-0.00B | $-0.00B | $-0.00B |
EBITDA | $-5.18M | $-5.41M | $-5.73M | $-4.87M | $-3.52M | $-5.19M | $-4.28M | $-3.82M | $-2.14M | $-4.39M | $-4.06M | $-3.47M | $-4.15M | $-2.48M | $-2.45M | $-2.89M | $-1.70M | $-832.76K | $-476.74K | $-674.63K |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1851.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | $-5.18M | $-5.41M | $-5.73M | $-4.88M | $-3.52M | $-5.19M | $-4.29M | $-3.83M | $-2.15M | $-4.39M | $-4.07M | $-3.51M | $-4.15M | $-2.48M | $-2.45M | $-2.90M | $-1.70M | $-833.42K | $-477.28K | $-675.17K |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1868.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income Expenses Net | $673.88K | $448.95K | $291.19K | $691.46K | $362.17K | $443.90K | $418.50K | $445.17K | $-119.42K | $-97.56K | $-55.38K | $-29.03K | $94.90K | $162.61K | $- | $- | $- | $- | $- | $- |
Income Before Tax | $-4.51M | $-4.96M | $-5.44M | $-4.19M | $-3.16M | $-4.75M | $-3.87M | $-3.38M | $-2.26M | $-4.49M | $-4.12M | $-3.54M | $-4.05M | $-2.32M | $-2.45M | $-2.90M | $-1.70M | $-833.42K | $-477.28K | $-675.17K |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -1603.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | $- | $-0.00B | $--0.00B | $-0.00B | $-246.39K | $-117.82K | $-418.50K | $- | $119.42K | $97.56K | $55.38K | $29.03K | $-77.22K | $-47.89K | $-0.00B | $-5.91B | $- | $- | $- | $- |
Net Income | $-4.51M | $-4.96M | $-5.44M | $-4.19M | $-3.16M | $-4.75M | $-3.45M | $-3.38M | $-2.38M | $-4.59M | $-4.18M | $-3.54M | $-4.05M | $-2.32M | $-2.45M | $-2.90M | $-1.70M | $-833.42K | $-477.28K | $-675.17K |
Net Income Ratio | 0.00% | 0.00% | 0.00% | -1603.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | $-0.42 | $-0.46 | $-0.51 | $-0.39 | $-0.29 | $-0.44 | $-0.32 | $0.00 | $-0.22 | $-0.42 | $-0.38 | $-0.32 | $-0.36 | $-0.21 | $-0.24 | $-0.47 | $-0.27 | $-0.31 | $-0.08 | $-0.11 |
EPS Diluted | $-0.42 | $-0.46 | $-0.51 | $-0.39 | $-0.29 | $-0.44 | $-0.32 | $0.00 | $-0.22 | $-0.42 | $-0.38 | $-0.32 | $-0.36 | $-0.21 | $-0.24 | $-0.47 | $-0.27 | $-0.31 | $-0.08 | $-0.11 |
Weighted Average Shares Outstanding | 10.76M | 10.76M | 10.74M | 10.80M | 10.86M | 10.86M | 10.86M | - | 10.84M | 10.83M | 10.88M | 11.17M | 11.19M | 11.18M | 10.07M | 6.22M | 6.22M | 2.72M | 6.03M | 6.22M |
Weighted Average Shares Outstanding Diluted | 10.76M | 10.76M | 10.74M | 10.80M | 10.86M | 10.86M | 10.86M | - | 10.84M | 10.83M | 10.88M | 11.19M | 11.19M | 11.18M | 10.07M | 6.22M | 6.22M | 2.72M | 6.03M | 6.22M |
SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Cash and Cash Equivalents | $21.94M | $37.20M | $51.52M | $19.23M | $1.23M |
Short Term Investments | $19.36M | $17.99M | $19.20M | $- | $- |
Cash and Short Term Investments | $41.30M | $55.20M | $70.73M | $19.23M | $1.23M |
Net Receivables | $- | $- | $- | $- | $- |
Inventory | $- | $-592.00K | $-181.00K | $- | $- |
Other Current Assets | $1.61M | $3.53M | $1.03M | $806.00K | $-0.00B |
Total Current Assets | $43.34M | $58.72M | $72.72M | $20.24M | $1.23M |
Property Plant Equipment Net | $280.42K | $95.69K | $216.19K | $21.51K | $8.76K |
Goodwill | $- | $- | $- | $- | $- |
Intangible Assets | $- | $- | $- | $- | $- |
Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
Long Term Investments | $- | $- | $1.00M | $- | $- |
Tax Assets | $- | $- | $- | $- | $- |
Other Non-Current Assets | $25.87K | $17.89K | $17.89K | $101.20K | $191.00K |
Total Non-Current Assets | $306.29K | $113.58K | $1.23M | $122.71K | $199.76K |
Other Assets | $- | $- | $- | $- | $- |
Total Assets | $43.65M | $58.84M | $73.95M | $20.36M | $1.43M |
Account Payables | $- | $932.41K | $681.11K | $432.34K | $478.29K |
Short Term Debt | $172.97K | $52.89K | $152.06K | $- | $- |
Tax Payables | $- | $- | $- | $- | $- |
Deferred Revenue | $- | $-2.75M | $-2.17M | $- | $- |
Other Current Liabilities | $2.51M | $1.81M | $1.49M | $120.00K | $11.00K |
Total Current Liabilities | $2.68M | $2.80M | $2.33M | $552.34K | $489.29K |
Long Term Debt | $61.50K | $- | $52.89K | $108.50K | $- |
Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
Other Non-Current Liabilities | $- | $- | $- | $- | $- |
Total Non-Current Liabilities | $61.50K | $52.89K | $52.89K | $108.50K | $- |
Other Liabilities | $- | $-52.89K | $- | $- | $- |
Total Liabilities | $2.74M | $2.80M | $2.38M | $660.84K | $489.29K |
Preferred Stock | $- | $- | $- | $- | $14.02K |
Common Stock | $1.07K | $1.09K | $1.11K | $-0.00B | $11.37K |
Retained Earnings | $-55.24M | $-39.28M | $-25.02M | $-12.66M | $-6.75M |
Accumulated Other Comprehensive Income Loss | $-107.46K | $-371.39K | $-92.69K | $--0.00B | $- |
Other Total Stockholders Equity | $96.26M | $95.69M | $96.69M | $32.36M | $7.69M |
Total Stockholders Equity | $40.91M | $56.04M | $71.57M | $19.70M | $943.28K |
Total Equity | $40.91M | $56.04M | $71.57M | $19.70M | $943.28K |
Total Liabilities and Stockholders Equity | $43.65M | $58.84M | $73.95M | $20.36M | $1.43M |
Minority Interest | $- | $- | $- | $- | $- |
Total Liabilities and Total Equity | $43.65M | $58.84M | $73.95M | $20.36M | $1.43M |
Total Investments | $19.36M | $17.99M | $19.20M | $- | $- |
Total Debt | $234.47K | $52.89K | $204.95K | $108.50K | $- |
Net Debt | $-21.70M | $-37.15M | $-51.32M | $-19.12M | $-1.23M |
Balance Sheet Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and Cash Equivalents | $8.10M | $12.98M | $18.36M | $21.94M | $25.57M | $28.42M | $32.48M | $37.20M | $39.26M | $43.36M | $46.65M | $51.52M | $54.67M | $61.35M | $81.37M | $19.23M | $20.80M | $23.80M | $634.25K | $1.23M |
Short Term Investments | $19.95M | $20.29M | $20.00M | $19.36M | $19.35M | $19.53M | $19.06M | $17.99M | $18.57M | $18.79M | $18.56M | $19.20M | $19.16M | $18.23M | $- | $- | $- | $- | $- | $- |
Cash and Short Term Investments | $28.05M | $33.26M | $38.36M | $41.30M | $44.93M | $47.95M | $51.54M | $55.20M | $57.83M | $62.15M | $65.22M | $70.73M | $73.83M | $79.59M | $81.37M | $19.23M | $20.80M | $23.80M | $634.25K | $1.23M |
Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $-305.00K | $-339.00K | $-228.00K | $-181.00K | $- | $- | $- | $- | $- | $- | $- | $- |
Other Current Assets | $1.87M | $2.03M | $1.11M | $2.04M | $2.50M | $4.95M | $3.63M | $3.53M | $4.19M | $1.33M | $293.00K | $1.03M | $1.46M | $1.86M | $360.00K | $806.00K | $2.98M | $1.80M | $132.15K | $-0.00B |
Total Current Assets | $29.92M | $35.29M | $39.47M | $43.34M | $47.43M | $51.04M | $55.17M | $58.72M | $62.02M | $65.66M | $67.66M | $72.72M | $76.34M | $82.13M | $82.48M | $20.24M | $22.48M | $25.60M | $766.39K | $1.23M |
Property Plant Equipment Net | $335.57K | $263.34K | $237.49K | $280.42K | $319.66K | $358.20K | $308.79K | $95.69K | $126.73K | $157.75K | $180.29K | $216.19K | $251.67K | $283.10K | $20.16K | $21.51K | $17.61K | $15.38K | $8.22K | $8.76K |
Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $541.18K | $541.18K | $1.00M | $1.00M | $- | $- | $- | $- | $- | $- | $- |
Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Non-Current Assets | $36.74K | $32.02K | $25.87K | $25.87K | $25.87K | $25.87K | $32.97K | $17.89K | $17.89K | $17.89K | $17.89K | $17.89K | $17.89K | $17.89K | $- | $101.20K | $- | $- | $263.38K | $191.00K |
Total Non-Current Assets | $372.30K | $295.35K | $263.36K | $306.29K | $345.53K | $384.07K | $341.75K | $113.58K | $144.62K | $716.82K | $739.36K | $1.23M | $1.27M | $300.99K | $20.16K | $122.71K | $17.61K | $15.38K | $271.60K | $199.76K |
Other Assets | $- | $- | $-0.00B | $- | $- | $- | $- | $- | $-0.00B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Assets | $30.29M | $35.59M | $39.73M | $43.65M | $47.77M | $51.43M | $55.51M | $58.84M | $62.16M | $66.38M | $68.40M | $73.95M | $77.61M | $82.43M | $82.50M | $20.36M | $22.49M | $25.61M | $1.04M | $1.43M |
Account Payables | $- | $4.44M | $1.61M | $942.21K | $2.09M | $2.85M | $1.19M | $- | $985.97K | $2.02M | $690.65K | $681.11K | $722.64K | $1.09M | $664.53K | $432.34K | $805.56K | $467.99K | $439.26K | $478.29K |
Short Term Debt | $197.29K | $328.00K | $178.02K | $172.97K | $336.03K | $326.29K | $119.58K | $52.89K | $92.02K | $130.71K | $155.19K | $152.06K | $148.96K | $145.90K | $- | $- | $- | $102.83K | $53.27K | $- |
Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Deferred Revenue | $- | $-4.44M | $-3.78M | $-1.74K | $-2.09M | $-2.85M | $-2.67M | $- | $-3.05M | $-5.17B | $-2.92M | $-2.33B | $-1.64M | $- | $- | $- | $- | $- | $-439.26K | $- |
Other Current Liabilities | $3.40M | $-164.00K | $2.16M | $1.56M | $-168.01K | $-163.15K | $1.49M | $2.75M | $2.06M | $3.16M | $2.23M | $1.49M | $914.00K | $1.45M | $- | $120.00K | $9.00K | $1.71M | $9.00K | $11.00K |
Total Current Liabilities | $3.60M | $4.60M | $3.95M | $2.68M | $2.25M | $3.02M | $2.79M | $2.80M | $3.14M | $5.30M | $3.07M | $2.33M | $1.79M | $2.69M | $664.53K | $552.34K | $814.56K | $2.28M | $501.53K | $489.29K |
Long Term Debt | $93.95K | $54.69K | $15.56K | $61.50K | $106.52K | $150.71K | $140.63K | $- | $- | $- | $13.30K | $52.89K | $92.02K | $130.71K | $108.50K | $108.50K | $108.50K | $108.50K | $- | $- |
Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Non-Current Liabilities | $93.95K | $54.69K | $15.56K | $61.49K | $106.52K | $150.71K | $140.63K | $- | $92.02K | $5.30M | $13.30K | $52.89K | $92.02K | $130.71K | $108.50K | $108.50K | $108.50K | $108.50K | $- | $- |
Other Liabilities | $- | $-0.00B | $-0.00B | $-0.00B | $- | $- | $- | $- | $-92.02K | $-5.30M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities | $3.70M | $4.66M | $3.97M | $2.74M | $2.36M | $3.17M | $2.93M | $2.80M | $3.14M | $5.30M | $3.09M | $2.38M | $1.88M | $2.82M | $773.03K | $660.84K | $923.06K | $2.39M | $501.53K | $489.29K |
Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-0.00B | $-0.00B | $14.02K |
Common Stock | $1.08K | $1.08K | $1.08K | $1.07K | $1.09K | $1.09K | $1.09K | $1.09K | $1.09K | $1.08K | $1.08K | $1.11K | $1.12K | $1.12K | $1.12K | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $11.37K |
Retained Earnings | $-70.15M | $-65.64M | $-60.69M | $-55.24M | $-51.06M | $-47.90M | $-43.15M | $-39.28M | $-35.90M | $-33.64M | $-29.14M | $-25.02M | $-21.48M | $-17.43M | $-15.11M | $-12.66M | $-9.76M | $-8.06M | $-7.23M | $-6.75M |
Accumulated Other Comprehensive Income Loss | $-25.26K | $-6.58K | $1.86K | $-107.46K | $-138.79K | $-261.84K | $-299.68K | $-371.39K | $-435.04K | $-348.48K | $-311.47K | $-92.69K | $-102.69K | $-47.56K | $-0.00B | $--0.00B | $--0.00B | $--0.00B | $- | $- |
Other Total Stockholders Equity | $96.77M | $96.58M | $96.45M | $96.26M | $96.61M | $96.42M | $96.02M | $95.69M | $95.36M | $95.06M | $94.77M | $96.69M | $97.31M | $97.09M | $96.84M | $32.36M | $31.33M | $31.29M | $7.77M | $7.69M |
Total Stockholders Equity | $26.60M | $30.93M | $35.77M | $40.91M | $45.41M | $48.26M | $52.58M | $56.04M | $59.03M | $61.08M | $65.32M | $71.57M | $75.73M | $79.61M | $81.73M | $19.70M | $21.57M | $23.23M | $536.47K | $943.28K |
Total Equity | $26.60M | $30.93M | $35.77M | $40.91M | $45.41M | $48.26M | $52.58M | $56.04M | $59.03M | $61.08M | $65.32M | $71.57M | $75.73M | $79.61M | $81.73M | $19.70M | $21.57M | $23.23M | $536.47K | $943.28K |
Total Liabilities and Stockholders Equity | $30.29M | $35.59M | $39.73M | $43.65M | $47.77M | $51.43M | $55.51M | $58.84M | $62.16M | $66.38M | $68.40M | $73.95M | $77.61M | $82.43M | $82.50M | $20.36M | $22.49M | $25.61M | $1.04M | $1.43M |
Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities and Total Equity | $30.29M | $35.59M | $39.73M | $43.65M | $47.77M | $51.43M | $55.51M | $58.84M | $62.16M | $66.38M | $68.40M | $73.95M | $77.61M | $82.43M | $82.50M | $20.36M | $22.49M | $25.61M | $1.04M | $1.43M |
Total Investments | $19.95M | $20.29M | $20.00M | $19.36M | $19.35M | $19.53M | $19.06M | $17.99M | $18.57M | $18.79M | $18.56M | $19.20M | $19.16M | $18.23M | $- | $- | $- | $- | $- | $- |
Total Debt | $291.24K | $218.70K | $193.58K | $234.47K | $274.53K | $313.86K | $260.22K | $52.89K | $92.02K | $130.71K | $168.49K | $204.95K | $240.98K | $276.60K | $108.50K | $108.50K | $108.50K | $211.33K | $53.27K | $- |
Net Debt | $-7.81M | $-12.76M | $-18.16M | $-21.70M | $-25.30M | $-28.11M | $-32.22M | $-37.15M | $-39.17M | $-43.23M | $-46.48M | $-51.32M | $-54.43M | $-61.08M | $-81.27M | $-19.12M | $-20.69M | $-23.59M | $-580.98K | $-1.23M |
Annual Cash Flow
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Net Income | $-15.96M | $-14.26M | $-12.36M | $-5.91M | $-2.43M |
Depreciation and Amortization | $14.62K | $10.08K | $6.76K | $3.39K | $1.63K |
Deferred Income Tax | $- | $- | $112.56K | $-1.08M | $251.65K |
Stock Based Compensation | $1.07M | $1.19M | $961.54K | $1.19M | $117.76K |
Change in Working Capital | $538.02K | $-611.86K | $599.96K | $-939.06K | $180.88K |
Accounts Receivables | $- | $-158.40K | $-71.66K | $- | $- |
Inventory | $- | $- | $- | $- | $- |
Accounts Payables | $- | $580.36K | $1.62M | $117.17K | $372.66K |
Other Working Capital | $538.02K | $-1.03M | $-950.47K | $-1.06M | $-191.79K |
Other Non Cash Items | $-5.17K | $906.49K | $90.66K | $1.08M | $-251.65K |
Net Cash Provided by Operating Activities | $-14.35M | $-12.77M | $-10.59M | $-5.65M | $-2.13M |
Investments in Property Plant and Equipment | $-18.73K | $-27.84K | $-15.50K | $-16.14K | $-5.72K |
Acquisitions Net | $- | $-179.27M | $19.53B | $- | $- |
Purchases of Investments | $-8.20M | $-3.91M | $-19.58M | $- | $- |
Sales Maturities of Investments | $7.28M | $4.12M | $64.09K | $- | $- |
Other Investing Activities | $--0.00B | $179.27M | $-19.53B | $-5.72M | $- |
Net Cash Used for Investing Activities | $-930.21K | $179.27K | $-19.53M | $-16.14K | $-5.72K |
Debt Repayment | $- | $- | $- | $108.50K | $- |
Common Stock Issued | $- | $- | $69.00M | $26.25M | $2.92M |
Common Stock Repurchased | $-500.00K | $-2.48M | $-939.67K | $- | $- |
Dividends Paid | $- | $- | $- | $- | $- |
Other Financing Activities | $- | $-2.48M | $-5.58M | $26.25M | $2.92M |
Net Cash Used Provided by Financing Activities | $-500.00K | $-2.18K | $63.42M | $23.66M | $2.92M |
Effect of Forex Changes on Cash | $-28.46K | $-10.61K | $1.07K | $- | $- |
Net Change in Cash | $-15.81M | $-14.78M | $33.30M | $18.00M | $786.87K |
Cash at End of Period | $21.94M | $37.74M | $52.52M | $19.23M | $1.23M |
Cash at Beginning of Period | $37.74M | $52.52M | $19.23M | $1.23M | $445.16K |
Operating Cash Flow | $-14.35M | $-12.77M | $-10.59M | $-5.65M | $-2.13M |
Capital Expenditure | $-18.73K | $-27.84K | $-15.50K | $-16.14K | $-5.72K |
Free Cash Flow | $-14.37M | $-12.80M | $-10.61M | $-5.67M | $-2.13M |
Cash Flow Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | $-4.51M | $-4.96M | $-5.44M | $-4.19M | $-3.16M | $-4.75M | $-3.87M | $-3.38M | $-2.26M | $-4.49M | $-4.12M | $-3.54M | $-4.05M | $-2.32M | $-2.45M | $-2.90M | $-1.70M | $-833.42K | $-477.28K | $-675.17K |
Depreciation and Amortization | $4.39K | $46.27K | $4.06K | $44.32K | $3.71K | $3.51K | $3.42K | $2.76K | $2.95K | $2.38K | $1.99K | $1.99K | $1.85K | $1.58K | $1.34K | $1.09K | $1.09K | $-0.00B | $-0.00B | $-0.00B |
Deferred Income Tax | $- | $- | $- | $180.44K | $95.50K | $38.93K | $- | $- | $- | $312.05K | $225.24K | $206.88K | $14.91K | $- | $- | $- | $- | $- | $- | $- |
Stock Based Compensation | $179.17K | $134.17K | $134.06K | $150.84K | $190.75K | $392.39K | $333.53K | $330.10K | $301.11K | $289.53K | $267.00K | $245.93K | $224.41K | $245.68K | $245.52K | $1.02M | $43.51K | $105.36K | $18.46K | $63.40K |
Change in Working Capital | $-914.35K | $-301.64K | $2.13M | $879.22K | $-780.24K | $679.39K | $-240.35K | $380.34K | $-2.38M | $1.12M | $263.66K | $977.34K | $-867.23K | $428.85K | $60.99K | $301.95K | $-1.23M | $236.52K | $-244.77K | $-97.65K |
Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Accounts Payables | $-1.03M | $661.18K | $1.27M | $419.92K | $-767.87K | $179.07K | $-67.30K | $- | $-2.14M | $2.28M | $742.52K | $1.49M | $-543.46K | $513.54K | $164.07K | $- | $- | $- | $- | $- |
Other Working Capital | $118.98K | $-962.83K | $860.13K | $459.31K | $-12.37K | $500.32K | $67.30K | $380.34K | $-237.81K | $-1.16M | $-478.86K | $-438.94K | $-323.77K | $-84.69K | $-103.08K | $-0.00B | $-1.60K | $-0.00B | $-244.77K | $--0.00B |
Other Non Cash Items | $-345.76K | $-544.40K | $-1.03M | $-454.25K | $39.61K | $40.25K | $14.01K | $--0.00B | $297.86K | $36.15K | $36.15K | $275.99K | $12.36K | $-85.12K | $84.13K | $--0.00B | $-0.00B | $-0.00B | $--0.00B | $-0.00B |
Net Cash Provided by Operating Activities | $-5.58M | $-5.19M | $-3.07M | $-3.39M | $-3.61M | $-3.59M | $-3.76M | $-2.67M | $-4.04M | $-2.73M | $-3.33M | $-2.04M | $-4.68M | $-1.73M | $-2.14M | $-1.57M | $-2.89M | $-490.87K | $-703.05K | $-708.88K |
Investments in Property Plant and Equipment | $-3.03K | $-4.27K | $-2.22K | $-5.08K | $-4.78K | $- | $-8.88K | $-6.96K | $-6.71K | $-14.18K | $- | $--0.00B | $-3.48K | $-12.01K | $- | $-4.99K | $-3.32K | $--0.00B | $- | $- |
Acquisitions Net | $- | $- | $- | $--0.00B | $--0.00B | $- | $-2.15M | $- | $-0.00B | $2.02M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Purchases of Investments | $-3.12M | $-8.35M | $-6.01M | $-1.56M | $-731.49K | $-2.81M | $-3.10M | $-590.18K | $-1.32M | $-2.00M | $- | $-298.05K | $-999.02K | $-18.28M | $- | $- | $- | $- | $- | $- |
Sales Maturities of Investments | $-13.61M | $8.15M | $5.46M | $1.82M | $968.00K | $2.35M | $2.15M | $1.20M | $1.25M | $1.49M | $176.52K | $64.09K | $- | $- | $- | $- | $- | $- | $- | $- |
Other Investing Activities | $17.41M | $--0.00B | $--0.00B | $-0.00B | $-0.00B | $--0.00B | $2.15M | $- | $--0.00B | $-2.02M | $-0.00B | $64.09K | $-3.48K | $-18.28K | $- | $-16.13M | $- | $- | $- | $- |
Net Cash Used for Investing Activities | $680.35K | $-202.06K | $-556.17K | $256.18K | $231.73K | $-457.24K | $-960.88K | $602.86K | $-74.36K | $-525.75K | $176.52K | $-233.96K | $-1.00M | $-18.29M | $- | $-4.99K | $-3.32K | $--0.00B | $- | $- |
Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-102.83K | $158.07K | $53.27K | $- |
Common Stock Issued | $-54.72K | $- | $54.72K | $- | $- | $- | $- | $- | $- | $- | $- | $66.86K | $- | $--0.00B | $69.00M | $- | $52.00K | $- | $- | $- |
Common Stock Repurchased | $- | $- | $- | $-500.00K | $- | $- | $- | $- | $- | $- | $-2.48M | $-939.67K | $- | $--0.00B | $- | $- | $- | $- | $- | $- |
Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Financing Activities | $11.99K | $- | $54.72K | $- | $- | $- | $- | $-2.48M | $- | $- | $299.79K | $-872.81K | $- | $- | $-4.71M | $--0.00B | $- | $23.50M | $52.00K | $- |
Net Cash Used Provided by Financing Activities | $11.99K | $- | $54.72K | $-500.00K | $- | $-690.80K | $- | $- | $- | $- | $-2.18K | $-872.81K | $- | $--0.00B | $64.29M | $--0.00B | $-102.83K | $23.66M | $105.27K | $- |
Effect of Forex Changes on Cash | $16.17K | $11.32K | $-9.83K | $-4.81K | $-12.24K | $-6.43K | $-4.98K | $9.90K | $7.65K | $-30.43K | $2.28K | $-0.00B | $- | $- | $- | $- | $- | $- | $- | $- |
Net Change in Cash | $-4.87M | $-5.38M | $-3.58M | $-3.63M | $-3.39M | $-4.06M | $-4.72M | $-2.06M | $-4.10M | $-3.29M | $-5.33M | $-3.14M | $-5.69M | $-20.02M | $62.14M | $-1.57M | $-3.00M | $23.16M | $-597.78K | $-708.88K |
Cash at End of Period | $8.10M | $12.98M | $18.36M | $21.94M | $25.57M | $28.96M | $33.02M | $37.74M | $39.80M | $43.90M | $47.19M | $52.52M | $55.67M | $61.35M | $81.37M | $19.23M | $20.80M | $23.80M | $634.25K | $1.23M |
Cash at Beginning of Period | $12.98M | $18.36M | $21.94M | $25.57M | $28.96M | $33.02M | $37.74M | $39.80M | $43.90M | $47.19M | $52.52M | $55.67M | $61.35M | $81.37M | $19.23M | $20.80M | $23.80M | $634.25K | $1.23M | $1.94M |
Operating Cash Flow | $-5.58M | $-5.19M | $-3.07M | $-3.39M | $-3.61M | $-3.59M | $-3.76M | $-2.67M | $-4.04M | $-2.73M | $-3.33M | $-2.04M | $-4.68M | $-1.73M | $-2.14M | $-1.57M | $-2.89M | $-490.87K | $-703.05K | $-708.88K |
Capital Expenditure | $-3.03K | $-4.27K | $-2.22K | $-5.08K | $-4.78K | $- | $-8.88K | $-6.96K | $-6.71K | $-14.18K | $- | $--0.00B | $-3.48K | $-12.01K | $- | $-4.99K | $-3.32K | $--0.00B | $- | $- |
Free Cash Flow | $-5.59M | $-5.19M | $-3.07M | $-3.39M | $-3.62M | $-3.59M | $-3.77M | $-2.68M | $-4.04M | $-2.75M | $-3.33M | $-2.04M | $-4.69M | $-1.74M | $-2.14M | $-1.57M | $-2.89M | $-490.88K | $-703.05K | $-708.88K |
Lantern Pharma Stock Forecast
Analyst ratings, price targets, and earnings estimates for LTRN.
LTRN Analyst Ratings
Strong Buy
Based on 1 analysts in the past 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
Date | Analyst | Firm | Price Target | Price When Posted | Upside |
---|
Lantern Pharma Dividends
Explore Lantern Pharma's dividend history, including dividend yield, payout ratio, and historical payments.
Peers: Biotechnology
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
---|---|---|---|---|---|
![]() TFF Pharmaceuticals, Inc.
TFFP
|
$288.80K | $0.07 | $-11.85 | $-0.59 | $1.32 |
![]() Generation Bio Co.
GBIO
|
$54.77M | $0.82 | $-1.96 | $-0.84 | $0.52 |
![]() Lyra Therapeutics, Inc.
LYRA
|
$12.49M | $0.19 | $-1.26 | $-4.16 | $2.92 |
![]() Immunome, Inc.
IMNM
|
$956.83M | $11.30 | $-5.38 | $-1.99 | $1.77 |
![]() Cue Biopharma, Inc.
CUE
|
$83.62M | $1.32 | $-1.11 | $-2.38 | $3.26 |
Related Metrics
Explore detailed financial metrics and analysis for LTRN.